Maze Therapeutics (MAZE) Gains from Sales and Divestitures (2024 - 2025)
Maze Therapeutics' (MAZE) quarterly Gains from Sales and Divestitures came in at $1.1 million in Q4 2025, up 4198.55% year-on-year from $25930.0 in Q4 2024, and up 4198.55% quarter-over-quarter from $25930.0 in Q4 2024.
Maze Therapeutics (MAZE) Gains from Sales and Divestitures (2024 - 2025) Analysis & Trends
Maze Therapeutics has disclosed Gains from Sales and Divestitures across 2 years of filings, most recently posting $1.1 million for Q4 2025.
- Gains from Sales and Divestitures for Q4 2025 came in at $1.1 million, up 4198.55% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.1 million (up 4198.55% YoY), and the FY2025 annual result was $1.1 million, up 4198.55% from the prior year.
- Gains from Sales and Divestitures came in at $1.1 million for Q4 2025 at Maze Therapeutics, up from $25930.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $1.1 million in Q4 2025 to a low of $25930.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Maze Therapeutics | 1.31 Bn | 1.31 Bn | 18.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.11 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Dec 31, 2024 | 25,930.00 |
| Dec 31, 2024 | 25,930.00 |